GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (NAS:UTHR) » Definitions » Net Margin %

United Therapeutics (United Therapeutics) Net Margin %

: 35.32% (As of Dec. 2023)
View and export this data going back to 1999. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. United Therapeutics's Net Income for the three months ended in Dec. 2023 was $217 Mil. United Therapeutics's Revenue for the three months ended in Dec. 2023 was $615 Mil. Therefore, United Therapeutics's net margin for the quarter that ended in Dec. 2023 was 35.32%.

The historical rank and industry rank for United Therapeutics's Net Margin % or its related term are showing as below:

UTHR' s Net Margin % Range Over the Past 10 Years
Min: -7.21   Med: 35.46   Max: 44.64
Current: 42.31


UTHR's Net Margin % is ranked better than
96.49% of 1026 companies
in the Biotechnology industry
Industry Median: -163.08 vs UTHR: 42.31

United Therapeutics Net Margin % Historical Data

The historical data trend for United Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.21 34.71 28.23 37.56 42.31

United Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.88 47.52 43.45 43.91 35.32

Competitive Comparison

For the Biotechnology subindustry, United Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Therapeutics Net Margin % Distribution

For the Biotechnology industry and Healthcare sector, United Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Net Margin % falls into.



United Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

United Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=984.8/2327.5
=42.31 %

United Therapeutics's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=217.1/614.7
=35.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


United Therapeutics  (NAS:UTHR) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


United Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


United Therapeutics (United Therapeutics) Business Description

Traded in Other Exchanges
Address
1040 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Executives
Paul A Mahon officer: EVP & General Counsel
Nilda Mesa director C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Causey director
Martine A Rothblatt director, officer: Chief Executive Officer
Louis W Sullivan director
Judy D. Olian director 2000 AVENUE OF THE STARS 12TH FL, LOS ANGELES CA 90067
Michael Benkowitz officer: President and COO C/O UNITED THERAPEUTICS CORP, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Patusky director
Raymond Dwek director
Linda Maxwell director 1040 SPRING STREET, SILVER SPRING NC 27709
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Katherine J Klein director STEINBERG HALL-DIETRICH HALL, 3620 LOCUST WALK, PHILADELPHIA PA 19104
Richard Giltner director C/O UNITED THERAPEUTICS CORPORTION, 1735 CONNECTICUT AVE. NW, WASHINGTON DC 20009
Roger Jeffs director, officer: President and COO
David Zaccardelli officer: EVP & Chief Operating Officer 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069